Overcoming multidrug-resistance in vitro and in vivo using the novel P-glycoprotein inhibitor 1416

Bioscience Reports

Volumn 32, Issue 6, 2012, Pages 559-566

  Xu, Yan ^a   Zhi, Feng ^a   Xu, Guangming ^a   Tang, Xiaolei ^a   Lu, Sheng ^a   Wu, Jinhui ^a   Hu, Yiqiao ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

Calcium antagonism; Multidrug resistance; P glycoprotein; Phenoprolamine hydrochloride; Verapamil

Indexed keywords

1416; [1 (2,6 DIMETHYLPHENOXY) 2 (3,4 DIMETHOXYPHENYLETHYLAMINO)PROPANE HYDROCHLORIDE]; DOXORUBICIN; GLYCOPROTEIN P INHIBITOR; GLYCOPROTEIN P INHIBITOR 1416; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; UNCLASSIFIED DRUG; VERAPAMIL; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; K562 CELLS; KB CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; P-GLYCOPROTEIN; PHENETHYLAMINES; VERAPAMIL; VINBLASTINE;

MUS MUSCULUS;

EID: 84872422430     PISSN: 01448463     EISSN: 15734935     Source Type: Journal    
DOI: 10.1042/BSR20120020     Document Type: Article

References (39)

1. Shukla, S., Wu, C.P. and Ambudkar, S.V. (2008) Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert. Opin. Drug Metab. Toxicol. 4, 205-223 (Pubitemid 351308418)
2. Higgins, C.F. (2007) Multiple molecular mechanisms for multidrug-resistance transporters. Nature 446, 749-757
3. Ambudkar, S.V., Kimchi-Sarfaty, C., Sauna, Z.E. and Gottesman, M.M. (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22, 7468-7485 (Pubitemid 37487170)
4. Juliano, R.L. and Ling, V. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152-162
5. Liu, F.S. (2009) Mechanisms of chemotherapeutic drug resistance in cancer therapy - a quick review. Taiwan J. Obstet. Gynecol. 48, 239-244
6. Teodori, E., Dei, S., Martelli, C., Scapecchi, S. and Gualtieri, F. (2006) The functions and structure of ABC transporters: implications for the design of new inhibitors of Pgp and MRP1 to control multidrug resistance (MDR). Curr. Drug Targets 7, 893-909
7. Eckford, P.D. and Sharom, F.J. (2009) ABC efflux pump-based resistance to chemotherapy drugs. Chem. Rev. 109, 2989-3011
8. Krishna, R. and Mayer, L.D. (2000) Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci. 11, 265-283
9. Bradley, G., Sharma, R., Rajalakshmi, S. and Ling, V. (1992) P-glycoprotein expression during tumor progression in the rat liver. Cancer Res. 52, 5154-5161
10. Tsuruo, T., Iida, H., Tsukagoshi, S. and Sakurai, Y. (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res. 41, 1967-1972 (Pubitemid 11114605)
11. Twentyman, P.R., Fox, N.E. and White, D.J. (1987) Cyclosporin A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug-resistant human lung cancer cell line. Br. J. Cancer 56, 55-57 (Pubitemid 17097699)
12. Ferry, D.R., Traunecker, H. and Kerr, D.J. (1996) Clinical trials of P-glycoprotein reversal in solid tumours. Eur. J. Cancer 32A, 1070-1081
13. Warner, E., Hedley, D., Andrulis, I., Myers, R., Trudeau, M., Warr, D., Pritchard, K.I., Blackstein, M., Goss, P.E., Franssen, E. et al. (1998) Phase II study of dexverapamil plus anthracycline in patients with metastatic breast cancer who have progressed on the same anthracycline regimen. Clin. Cancer Res. 4, 1451-1457 (Pubitemid 28265228)
14. Cabot, M.C., Giuliano, A.E., Han, T.Y. and Liu, Y.Y. (1999) SDZ PSC 833, the cyclosporine A analogue and multidrug-resistance modulator, activates ceramide synthesis and increases vinblastine sensitivity in drug-sensitive and drug-resistant cancer cells. Cancer Res. 59, 880-885 (Pubitemid 29086743)
15. Thomas, H. and Coley, H.M. (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10, 159-165 (Pubitemid 36437822)
16. Wandel, C., Kim, R.B., Kajiji, S., Guengerich, P., Wilkinson, G.R. and Wood, A.J. (1999) P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res. 59, 3944-3948 (Pubitemid 29393559)
17. Fox, E. and Bates, S.E. (2007) Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev. Anticancer Ther. 7, 447-459 (Pubitemid 46681800)
18. Dantzig, A.H., Law, K.L., Cao, J. and Starling, J.J. (2001) Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic. Curr. Med. Chem. 8, 39-50
19. Fletcher, J.I., Haber, M., Henderson, M.J. and Norris, M.D. (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 10, 147-156
20. Modok, S., Mellor, H.R. and Callaghan, R. (2006) Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr. Opin. Pharmacol. 6, 350-354 (Pubitemid 44026037)
21. Pereira, E., Teodori, E., Dei, S., Gualtieri, F. and Garnier-Suillerot, A. (1995) Reversal of multidrug resistance by verapamil analogues. Biochem. Pharmacol. 50, 451-457
22. Hu, X.D. and Qian, J.Q. (2001) DDPH inhibited L-type calcium current and sodium current in single ventricular myocyte of guinea pig. Acta Pharmacol. Sin. 22, 415-419
23. Qian, J., Feng, G. and Liang, H. (1998) Action of DDPH in the interventional treatment of portal hypertension induced by liver cirrhosis in rabbits. J. Tongji Med. Univ. 18, 108-112
24. Xu, X., Sun, M., Zhi, F. and Hu, Y. (2006) Floating matrix dosage form for phenoporlamine hydrochloride based on gas forming agent: in vitro and in vivo evaluation in healthy volunteers. Int. J. Pharm. 310, 139-145 (Pubitemid 43287977)
25. Xia, L., Ni, P.Z. and Ji, M. (1984) Synthesis of mexiletine analogs. Yao Xue Xue Bao 19, 656-659
26. Ambudkar, S.V., Cardarelli, C.O., Pashinsky, I. and Stein, W.D. (1997) Relation between the turnover number for vinblastine transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. J. Biol. Chem. 272, 21160-21166 (Pubitemid 27373976)
27. Perloff, M.D., Stormer, E., von Moltke, L.L. and Greenblatt, D.J. (2003) Rapid assessment of P-glycoprotein inhibition and induction in vitro. Pharm. Res. 20, 1177-1183 (Pubitemid 36951842)
28. Stow, M.W. and Warr, J.R. (1991) Amplification and expression of MDR genes and flanking sequences in verapamil hypersensitive hamster cell lines. Biochim. Biophys. Acta 1092, 7-14
29. Hart, S.M., Ganeshaguru, K., Lyttelton, M.P., Prentice, H.G., Hoffbrand, A.V. and Mehta, A.B. (1993) Flow cytometric assessment of multidrug resistance (MDR) phenotype in acute myeloid leukaemia. Leuk. Lymphoma 11, 239-248 (Pubitemid 23323853)
30. Reue, K. (1998) mRNA quantitation techniques: considerations for experimental design and application. J. Nutr. 128, 2038-2044
31. Aleman, C., Annereau, J.P., Liang, X.J., Cardarelli, C.O., Taylor, B., Yin, J.J., Aszalos, A. and Gottesman, M.M. (2003) P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res. 63, 3084-3091 (Pubitemid 36735857)
32. Yague, E., Armesilla, A.L., Harrison, G., Elliott, J., Sardini, A., Higgins, C.F. and Raguz, S. (2003) P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. J. Biol. Chem. 278, 10344-10352 (Pubitemid 36800297)
33. Gottesman, M.M. and Pastan, I. (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385-427 (Pubitemid 23237876)
34. Wiese, M. and Pajeva, I.K. (2001) Structure-activity relationships of multidrug resistance reversers. Curr. Med. Chem. 8, 685-713 (Pubitemid 32409800)
35. Teodori, E., Dei, S., Quidu, P., Budriesi, R., Chiarini, A., Garnier-Suillerot, A., Gualtieri, F., Manetti, D., Romanelli, M.N. and Scapecchi, S. (1999) Design, synthesis, and in vitro activity of catamphiphilic reverters of multidrug resistance: discovery of a selective, highly efficacious chemosensitizer with potency in the nanomolar range. J. Med. Chem. 42, 1687-1697 (Pubitemid 29244962)
36. Aller, S.G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P.M., Trinh, Y.T., Zhang, Q., Urbatsch, I.L. and Chang, G. (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323, 1718-1722
37. Yusa, K. and Tsuruo, T. (1989) Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49, 5002-5006 (Pubitemid 19239333)
38. Zhong, N., Fang, Q.Z., Zhang, Y., Qian, J.Q. and Zhou, Z.N. (2000) Inhibitory effect of 1-(2, 6-dimethylphenoxy)-2-(3, 4-dimethoxyphenyl- ethylamino) propane hydrochloride on inward rectifier and delayed rectifier K+ currents in guinea pig ventricular myocytes. Acta Pharmacol. Sin. 21, 301-305 (Pubitemid 30220132)
39. Zhao, L., Yang, X., Xu, R., Wu, J., Gu, S., Zhang, L., Gong, P., Chen, H. and Zeng, F. (2009) Safety, tolerability and pharmacokinetics of phenoprolamine hydrochloride floating sustained-release tablets in healthy Chinese subjects. Int. J. Pharm. 377, 99-104